Quest Diagnostics Incorporated (DGX)vsWaters Corporation (WAT)
DGX
Quest Diagnostics Incorporated
$195.26
+0.57%
HEALTHCARE · Cap: $21.72B
WAT
Waters Corporation
$298.99
-0.19%
HEALTHCARE · Cap: $29.33B
Smart Verdict
WallStSmart Research — data-driven comparison
Quest Diagnostics Incorporated generates 249% more annual revenue ($11.04B vs $3.17B). WAT leads profitability with a 20.3% profit margin vs 9.0%. WAT appears more attractively valued with a PEG of 1.25. DGX earns a higher WallStSmart Score of 61/100 (C+).
DGX
Buy61
out of 100
Grade: C+
WAT
Buy60
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+2.6%
Fair Value
$214.96
Current Price
$195.26
$19.70 discount
Margin of Safety
-349.9%
Fair Value
$73.17
Current Price
$298.99
$225.82 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Strong operational efficiency at 33.8%
Safe zone — low bankruptcy risk
Every $100 of equity generates 29 in profit
Keeps 20 of every $100 in revenue as profit
Areas to Watch
Expensive relative to growth rate
Weak financial health signals
Moderate valuation
Earnings declined 3.1%
Comparative Analysis Report
WallStSmart ResearchBull Case : DGX
The strongest argument for DGX centers on Price/Book.
Bull Case : WAT
The strongest argument for WAT centers on Operating Margin, Altman Z-Score, Return on Equity. Profitability is solid with margins at 20.3% and operating margin at 33.8%. PEG of 1.25 suggests the stock is reasonably priced for its growth.
Bear Case : DGX
The primary concerns for DGX are PEG Ratio, Piotroski F-Score.
Bear Case : WAT
The primary concerns for WAT are P/E Ratio, EPS Growth.
Key Dynamics to Monitor
DGX profiles as a value stock while WAT is a mature play — different risk/reward profiles.
WAT carries more volatility with a beta of 1.20 — expect wider price swings.
DGX is growing revenue faster at 7.1% — sustainability is the question.
DGX generates stronger free cash flow (307M), providing more financial flexibility.
Bottom Line
DGX scores higher overall (61/100 vs 60/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Quest Diagnostics Incorporated
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Quest Diagnostics is an American clinical laboratory. A Fortune 500 company, Quest operates in the United States, Puerto Rico, Mexico, and Brazil. Quest also maintains collaborative agreements with various hospitals and clinics across the globe.
Waters Corporation
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Waters Corporation is a publicly traded Analytical Laboratory instrument and software company headquartered in Milford, Massachusetts.
Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?